MicroPort NeuroScientific has today announced the successful launch of its Numen coil embolisation system in Egypt, doing so in partnership with PentaMed.
The first case—a complex, large anterior communicating artery (ACom) aneurysm—was performed at Neuro Espitalia Hospital in Cairo, Egypt by Farouk Hassan. Seven Numen coils were deployed with Y-stenting, achieving complete aneurysm occlusion and delivering favourable clinical outcomes.
MicroPort claims that Numen, which is available in 177 specifications across three series—MicroFrame, MicroFill, and MicroFinish—features ultra-fine platinum-tungsten wires and a “distinctive” three-dimensional structure that combines flexibility with optimal support. Its design reduces pressure on the aneurysm wall and accommodates a wide variety of aneurysm morphologies, according to the company.
“This launch marks an exciting step forward as MicroPort NeuroScientific continues expanding access to innovative neurovascular solutions across this region,” the company also states in a recent press release.
Numen coils are currently commercially available in more than 30 countries and regions worldwide.
Late last year, in December, MicroPort NeuroTech—a subsidiary of MicroPort NeuroScientific—announced that it had received registration approval from the Mexican Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) for four key products: the Numen coil embolisation system, Numen FR coil detachment system, NeuroHawk thrombectomy device, and X-track intracranial distal access catheter.
The latter months of 2024 also saw MicroPort NeuroTech announce the completion of the first post-market implantation of its next-generation Tubridge Plus flow diverter in China, in addition to gaining US Food and Drug Administration (FDA) clearance for the Numen Silk coil embolisation system.
